Phase 3 Restless Legs Syndrome Trial, Recruiting NCT07199504 Sponsor: Yunfeng Xia Condition: Restless Legs Syndrome
Back to Restless Legs Syndrome

Phase 3 Restless Legs Syndrome Trial, Recruiting

NCT07199504
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been receiving regular kidney dialysis (hemodialysis) for at least 3 months
  • You are between 18 and 75 years old
  • You have been diagnosed with Restless Legs Syndrome (an uncomfortable urge to move your legs, especially at rest) and your symptoms are rated as moderate to severe based on a standard questionnaire
  • You are willing to participate and follow the requirements of the study

Who may not be able to join:

  • You have other conditions affecting your brain, muscles, or movement that could make it hard to assess your leg symptoms (confirm with trial site)
  • You are currently experiencing active bleeding, such as bleeding in your stomach, intestines, or brain
  • You have been taking a medication called dipyridamole for a long period of time
  • You have taken certain medications in the last 3 weeks that could affect Restless Legs Syndrome symptoms, such as some antidepressants, dopamine-related drugs, or lithium (confirm with trial site for the full list)
  • You have a history of a serious mental health (psychiatric) condition
  • You are currently pregnant or breastfeeding
  • You have had an allergic reaction to dipyridamole or cannot tolerate it
  • You are unable or unwilling to cooperate with the study requirements

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-023-89012687

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Yunfeng Xia
Registry
ClinicalTrials.gov
Start date
20 September 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

International Restless Legs Syndrome Study Group rating scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov